ELFP方案治疗晚期食管癌35例  

＂ELFP＂ Scheme;in the treatment of advanced esophageal cancer 35 cases

作　　者：庄海莲 赵梅[1] 

机构地区：[1]泰安市中医医院,山东泰安271000

出　　处：《中外医学研究》2010年第29期17-18,共2页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的 观察足叶乙甙（VP-16）联合氟尿嘧啶（5-FU）、亚叶酸钙（CF）、顺铂（DDP）组成的ELFP方案治疗晚期食管癌的近期疗效和毒副反应.方法 35例晚期食管癌患者,给予ELFP方案化疗.VP-16 60 mg/㎡,静脉滴注,第1天,第3天和第5天;CF 200 mg,静脉滴注第1天～第5天;5-FU 500 mg/㎡,静脉滴注d 1～5;DDP 20 mg/㎡,静脉滴注第1天～第5天,21 d为1个周期.结果 35例晚期食管癌患者均可评价疗效,总有效率60.0%,其中CR4例,10例复治组有效率50.0%,CR1例.毒副反应主要为剂量限制性毒性,表现为Ⅲ～IV度骨髓抑制（5.7%）.结论 ELFP方案治疗晚期食管癌有效率高,毒副反应可耐受.Objective To observe the etoposide （VP-16） combined with fluorouracil （5 -FU）,leucovorin （CF）,cisplatin （DDP） regimen consisting of ELFP advanced esophageal cancer efficacy and toxicity reaction. Methods 35 patients with advanced esophageal cancer patients, chemotherapy given EI.FP. VP - 16 60 mg/㎡ ,intravenous infusion, d 1,3,5 ; CF 200 rag, intravenous infusion d 1 - 5 ;5 - FU 500 mg/㎡,intravenous infusion d 1 -5;DDP 20mg / m , intravenous infusion d1 -5, 21 days for a period. Results 35 patients with advanced esophageal cancer patients can be evaluated, the total effective rate 60.0%, which CR4 cases, 10 cases re - treated group was 50.0%, CRI patients. Adverse reactions were dose - limiting toxicity, manifested as Ⅲ～IV treatment of advanced esophageal cancer is high, toxicity can be tolerated.

关 键 词：晚期食管癌 足叶乙甙 亚叶酸钙 氟尿嘧啶 顺铂 化疗 

分 类 号：R735.2[医药卫生—肿瘤]